Int Neurourol J > Volume 24(Suppl 1); 2020 > Article |
|
Identifier | Clinical trial phase | Type of SCI | No. of patients | Age (yr), range | Cell type | Delivery method | Efficacy | Safety |
---|---|---|---|---|---|---|---|---|
NCT01325103 [39] | Phase 1 | Thoracic or lumbar traumatic SCI (ASIA grade A) | 14 | 18–65 | Autologous BM-MSC | Intralesional injection after laminectomy and decompression of the spinal lesion area | Variably enhanced sensitivity below the injury area was observed. 8 patients: improvement of lower limb motor function, 7 patients: improvement of AIS, 3 patients: improvement of neuropathic pain | 14 Patients: discharge within 48 hours after surgery, 1: cerebrospinal leak related to surgery, no severe adverse events |
NCT02482194 [40] | Phase 1 | Chronic and subacute SCI | 9 | 18–50 | Autologous BM-MSCs | Intrathecal injection | At 1 year after treatment, no alteration in the hyperintense signal and no formation of ectopic tissue | No severe adverse event, 1 patient: severe headache, 2 patients: nonspecific tingling sensation |
NCT01909154 | Phase 1 | Chronic paraplegia (ASIA grade A) | 9 | 18–50 | Autologous BM-MSCs | Intrathecal injection (second injection at 3 months after the first injection) | Sensory recovery, improvement of chronic pain, presence of SSEPs | No severe adverse events, nausea, urinary tract infection, back pain, thoracic pain, muscle contracture, myalgia, headache |
NCT00816803 [41] | Phase1/2 | Chromic SCI with thoracic spinal trauma | 70 | 10–36 | Autologous BM-MSCs with physiotherapy (n = 50), standard rehabilitative therapy with physiotherapy (n = 20) | Intrathecal injection | Autologous BM-MSCs with physiotherapy group: 17 patients showed improvement of the ASIA score, 23 patients showed improvement of motor function | Headaches, mild pain |
NCT01274975 [42] | Phase 1 | Traumatic SCI (ASIA grade A or B) | 8 | 19–60 | Autologous ADSCs | Intravenous infusion | MRI at 12 weeks after therapy showed a reduction of injured lesions without significance. Conversion from ASIA A to ASIA C and improvement of motor and sensory function were noted in 1 patient | No severe adverse events |
NCT01393977 [43] | Phase 3 | Thoracolumbar SCI | 34 | 20–50 | UC-MSC transplantation group, rehabilitation therapy group, control group | Intrathecal injection | Seven of 10 patients treated with UC-MSCs showed significant improvement of motor function | Radiating neuralgia after UC-MSC transplantation; improvement within 24 hours |
SCI, spinal cord injury; ASIA, American Spinal Injury Association; BM-MSCs, bone marrow stem cells; AIS, Association Impairment Scale; SSEP, somatosensory evoked potential; ADSCs, adipose-derived mesenchymal stem cells; MRI, magnetic resonance imaging; UC-MSCs, umbilical cord mesenchymal stem cells.
Identifier | Clinical trial phase | Type of SCI | No. of patients | Age (yr), range | Cell type | Delivery method | Efficacy | UDS | Safety | |
---|---|---|---|---|---|---|---|---|---|---|
Completed trials | ||||||||||
NCT02152657 | Phase 1 | Chronic SCI (ASIA grade A) | 5 | 18–65 | Autologous BM-MSCs | Percutaneous administration | NR | NR | NR | |
NCT01325103 [39] | Phase 1 | Thoracic or lumbar traumatic SCI (ASIA grade A) | 14 | 18–65 | Autologous BM-MSCs | Intralesional injection after laminectomy and decompression of the spinal lesion area | Variably enhanced sensitivity below the injury area was observed. 9 patients: improvement of lower limb motor function, 7 patients: improvement of AIS, 3 patients: improvement of neuropathic pain | Increased maximum cystometric capacity without significance, significant improvement of compliance, improvement of bladder sensation. Urinary incontinence was not improved. CIC was needed after treatment | 14 patients: discharge within 48 hours after surgery, 1: cerebrospinal leak related to surgery, No severe adverse events | |
NCT01909154 | Phase 1 | Chronic paraplegia (ASIA grade A) | 9 | 18–50 | Autologous BM-MSCs | Intrathecal injection (second injection at 3 months after the first injection) | Sensory recovery, improvement of chronic pain, presence of SSEPs | Increased bladder compliance, decreased detrusor pressure | No severe adverse events, nausea, urinary tract infection, back pain, thoracic pain, muscle contracture, myalgia, headache | |
NCT02570932 | Phase 2 | Chronic SCI | 10 | 18–70 | Autologous BM-MSCs | Intrathecal injection | NR | NRa) | NR | |
NCT01393977 [43] | Phase 3 | Thoracolumbar SCI | 34 | 20–50 | UC-MSCs transplantation group, rehabilitation therapy group, control group | Intrathecal injection | Seven of 10 patients treated with UC-MSCs showed significant improvement of motor function. | Significantly increased maximum bladder capacity, significantly decreased detrusor pressure, increased maximum flow rate without significance | Radiating neuralgia after UC-MSC transplantation; improvement within 24 hours | |
Ongoing trials | ||||||||||
NCT03521336 | Phase 2 | Subacute SCI | 84 | 18–65 | BM-MSCs | Intrathecal injection | NR | NR | NR | |
NCT03521323 | Phase 2 | Early-stage of chronic SCI | 66 | ≥ 18 | BM-MSCs | Intrathecal injection | NR | NR | NR | |
NCT03003364 | Phase 1/2 | Chronic SCI | 10 | 18–65 | WJ-MSC | Intrathecal injection | NR | NR | NR | |
NCT02687672 | Phase 2 | Chronic complete SCI | 50 | 5–50 | Autologous BM-MSCs | NR | NR | NR | NR | |
NCT01772810 | Phase 1 | Chronic SCI | 8 | 18–65 | Human-spinal cord-derived neural stem cell | NR | NR | NR | NR |
SCI, spinal cord injury; UDS, urodynamic study; ASIA, American Spinal Injury Association; BM-MSCs, bone marrow stem cells; AIS, Association Impairment Scale; SSEP, somatosensory evoked potential; ADSCs, adipose-derived mesenchymal stem cells; BM-MSCs, umbilical cord mesenchymal stem cells; CIC, clean intermittent catheterization; WJ-MSCs, Wharton’s jelly mesenchymal stem cells; NR, not reported.